Isracann Biosciences Stock Performance
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Isracann Biosciences are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Isracann Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 2 M | |
| Total Cashflows From Investing Activities | -77.2 K |
Isracann |
Isracann Biosciences Relative Risk vs. Return Landscape
If you would invest 0.01 in Isracann Biosciences on August 31, 2024 and sell it today you would lose (0.01) from holding Isracann Biosciences or give up 100.0% of portfolio value over 90 days. Isracann Biosciences is currently producing negative expected returns and takes up 12.7% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Isracann, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Isracann Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Isracann Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Isracann Biosciences, and traders can use it to determine the average amount a Isracann Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.127
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ISCNF |
Estimated Market Risk
| 12.7 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.61 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Isracann Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Isracann Biosciences by adding Isracann Biosciences to a well-diversified portfolio.
Isracann Biosciences Fundamentals Growth
Isracann Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Isracann Biosciences, and Isracann Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Isracann Pink Sheet performance.
| Return On Equity | -2.53 | |||
| Return On Asset | -0.35 | |||
| Current Valuation | 2.16 M | |||
| Shares Outstanding | 175.99 M | |||
| Price To Book | 9.57 X | |||
| Price To Sales | 8.83 X | |||
| EBITDA | (4.64 M) | |||
| Cash And Equivalents | 310.61 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (1.75 M) | |||
| Earnings Per Share | (0.13) X | |||
| Total Asset | 4.09 M | |||
About Isracann Biosciences Performance
By analyzing Isracann Biosciences' fundamental ratios, stakeholders can gain valuable insights into Isracann Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Isracann Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Isracann Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. Isracann Biosciences Inc. was founded in 2010 and is headquartered in Vancouver, Canada. Isracann Biosciences is traded on OTC Exchange in the United States.Things to note about Isracann Biosciences performance evaluation
Checking the ongoing alerts about Isracann Biosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Isracann Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Isracann Biosciences generated a negative expected return over the last 90 days | |
| Isracann Biosciences has high historical volatility and very poor performance | |
| Isracann Biosciences has some characteristics of a very speculative penny stock | |
| Isracann Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Isracann Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Isracann Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Isracann Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Isracann to invest in growth at high rates of return. When we think about Isracann Biosciences' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (4.69 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Isracann Biosciences has accumulated about 310.61 K in cash with (1.75 M) of positive cash flow from operations. |
- Analyzing Isracann Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Isracann Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Isracann Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Isracann Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Isracann Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Isracann Biosciences' pink sheet. These opinions can provide insight into Isracann Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Isracann Pink Sheet analysis
When running Isracann Biosciences' price analysis, check to measure Isracann Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Isracann Biosciences is operating at the current time. Most of Isracann Biosciences' value examination focuses on studying past and present price action to predict the probability of Isracann Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Isracann Biosciences' price. Additionally, you may evaluate how the addition of Isracann Biosciences to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |